| Name | Title | Contact Details |
|---|
St. Joseph Health System is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Tawas City, MI. To find more information about St. Joseph Health System, please visit www.sjhsys.org
Uroplasty is a global medical company committed to offering transformative treatment options through specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Uroplasty’s products include the Urgent® PC Neuromodulation System, a non-drug, non-surgical office-based treatment for Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Urgent PC is an FDA-cleared system that delivers PTNS (Percutaneous Tibial Nerve Stimulation) and is also indicated for the treatment of fecal incontinence outside the US market. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent for female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Female SUI only in U.S.; male and female SUI outside the U.S. Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.
Aptihealth is improving higher acuity behavioral healthcare for underserved populations—one member at a time. The company`s virtual-first model and proprietary screening, assessment, and treatment programs give members fast, convenient access to precise, personalized care. Headquartered in Boston and employing over 150, aptihealth has raised over $65 million in funding from leading international equity firms. The company`s care program and data insights are driving breakthroughs in mental health understanding, treatment, outcomes, and cost reduction.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.
Martin-Deneen Associates Inc is a Grass Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.